146 related articles for article (PubMed ID: 36728824)
21. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
22. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
Clark C; McGhee P; Appelbaum PC; Kosowska-Shick K
Antimicrob Agents Chemother; 2011 May; 55(5):2344-51. PubMed ID: 21343467
[TBL] [Abstract][Full Text] [Related]
23. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
25. Antibiotic susceptibility of Kingella kingae isolates from respiratory carriers and patients with invasive infections.
Yagupsky P; Katz O; Peled N
J Antimicrob Chemother; 2001 Feb; 47(2):191-3. PubMed ID: 11157905
[TBL] [Abstract][Full Text] [Related]
26. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011).
Flamm RK; Sader HS; Jones RN
Braz J Infect Dis; 2014; 18(2):187-95. PubMed ID: 24513484
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Sader HS; Farrell DJ; Mendes RE; Flamm RK; Castanheira M; Jones RN
Diagn Microbiol Infect Dis; 2015 May; 82(1):78-84. PubMed ID: 25708896
[TBL] [Abstract][Full Text] [Related]
28. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
Richter SS; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Kroeger JS; Biek D; Critchley IA; Diekema DJ; Doern GV
Antimicrob Agents Chemother; 2011 Sep; 55(9):4154-60. PubMed ID: 21709080
[TBL] [Abstract][Full Text] [Related]
29. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
Alfouzan W; Boswihi SS; Dhar R; Udo E
J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of ceftaroline against mecC-positive MRSA isolates.
Armengol-Porta M; Tenorio-Abreu A; Bandt D; Coleman DC; Gavier-Widen D; Hotzel H; Kinnevey P; Lazaris A; Peters M; Rangstrup-Christensen L; Schlotter K; Shore AC; Ehricht R; Monecke S
J Glob Antimicrob Resist; 2016 Jun; 5():3-6. PubMed ID: 27436457
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
33. Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.
Goldstein EJ; Citron DM; Merriam CV; Tyrrell KL
Antimicrob Agents Chemother; 2012 Dec; 56(12):6319-23. PubMed ID: 23027193
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
35. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
McGee L; Biek D; Ge Y; Klugman M; du Plessis M; Smith AM; Beall B; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2009 Feb; 53(2):552-6. PubMed ID: 19015339
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections.
Piérard D; Stone GG
J Glob Antimicrob Resist; 2021 Sep; 26():4-10. PubMed ID: 34022417
[TBL] [Abstract][Full Text] [Related]
37. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
[TBL] [Abstract][Full Text] [Related]
38. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Vidaillac C; Leonard SN; Sader HS; Jones RN; Rybak MJ
Antimicrob Agents Chemother; 2009 Jun; 53(6):2360-6. PubMed ID: 19349512
[TBL] [Abstract][Full Text] [Related]
40. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
